GlobeNewswire Inc | Jan 26, 2022 07:00AM EST

January 26, 2022

NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B.Riley Securities 2022 Oncology Conference on Thursday, 27 January 2022 at 4:00 p.m. EDT (U.S. and Canada) to provide Company updates.

Date: Thursday, 27 January 2022Time: 4:00 p.m. Eastern Daylight Savings Time (US and Canada)Webcast: Click this link to access: https://www.webcaster4.com/Webcast/Page/ 2828/44467 Location: Track 1

About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tizianas innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tizianas two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tizianas technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:Hana Malik, Business Development and Investor Relations Manager +44 (0) 207 495 2379email: info@tizianalifesciences.com

United States:Investors:Irina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com